At the news
? BULLISHIMPACT 7/10 8-K filed Apr 15, 2026 at 07:31 ET
Arbutus Biopharma announced that the FDA has granted Fast Track designation for its investigational therapy imdusiran for the treatment of chronic hepatitis B. This designation is intended to expedite the development and review of therapies for serious conditions with unmet medical need, based on early clinical data showing functional cures in some patients.
- FDA granted Fast Track designation to imdusiran for chronic hepatitis B (cHBV) treatment
- Fast Track status allows for more frequent FDA interactions and potential for Accelerated Approval, Priority Review, or Rolling Review
- In Phase 2a trials, 8 patients achieved functional cure, with 6 sustaining it for over two years; an additional 41 patients remained off nucleos(t)ide analogue therapy for at least 48 weeks
- Functional cure is defined as sustained HBsAg seroclearance and undetectable HBV DNA after 24 weeks off treatment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access